Latest News on ELVN

Financial News Based On Company


Advertisement
Advertisement

Enliven Therapeutics CMO Helen Collins sells $234,203 in stock By Investing.com

https://in.investing.com/news/stock-market-news/enliven-therapeutics-cmo-helen-collins-sells-234203-in-stock-93CH-5716793
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, sold 5,000 shares of company stock worth $234,203 on November 17, 2026, through a Rule 10b5-1 trading plan. This sale followed her exercise of stock options and occurred as Enliven shares have significantly increased over the past year. Despite the stock appearing overvalued by some metrics, analysts largely maintain optimistic "Strong Buy" ratings, especially following recent positive updates on the ENABLE-2 Phase 3 study for its lead asset.

Form 4 Enliven Therapeutics Inc: Helen Louise Collins (CHIEF MEDICAL OFFICER) For: 17 November

https://au.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-helen-louise-collins-chief-medical-officer-for-17-november-93CH-4785448
This article reports on a Form 4 filing for Enliven Therapeutics Inc, indicating a transaction by Helen Louise Collins, the Chief Medical Officer, for November 17. The filing is a standard disclosure of insider trading activity. The article provides the basic details of the filing without further elaboration on the nature or value of the transaction.

ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readout

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4665871:0-elvn-second-line-plus-phase-iii-launch-is-imminent-with-a-potential-early-2029-readout/
Enliven Therapeutics, Inc. (ELVN) is preparing for the imminent launch of a second-line-plus phase III clinical trial, with enrollment expected to take approximately 18 months and a potential readout in early 2029. Additionally, frontline development is progressing towards a possible pivotal start in the first half of 2028, and an Investigational New Drug (IND) application for Graves' disease is anticipated in early 2027. This information is based on an AI-generated summary of Enliven Therapeutics' audio transcript from the Jefferies Global Healthcare Conference on November 17, 2026.

Enliven Therapeutics Welcomes The Max Foundation CEO Pat Garcia-Gonzalez

https://oncodaily.com/voices/enliven-therapeutics-630844
Enliven Therapeutics hosted Pat Garcia-Gonzalez, CEO of The Max Foundation, at a recent company offsite to highlight The Max Foundation's efforts in expanding access to cancer treatment worldwide. The event emphasized the importance of patient-centric care and the foundation's work in providing diagnostic testing, treatment, and support for patients, especially those with CML in underserved communities. Enliven Therapeutics expressed gratitude for the opportunity to collaborate with an organization dedicated to improving patients' lives.

Trading Systems Reacting to (ELVN) Volatility

https://news.stocktradersdaily.com/news_release/34/Trading_Systems_Reacting_to_ELVN_Volatility_111026112802_1794371282.html
This article from Stock Traders Daily analyzes Enliven Therapeutics Inc. (NASDAQ: ELVN), indicating a strong sentiment across all horizons supporting an overweight bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss levels. The analysis highlights an exceptional 69.0:1 risk-reward setup targeting a 20.5% gain versus 0.3% risk.
Advertisement

Enliven Therapeutics, Inc (ELVN) Tops Q3 EPS by 9c

https://www.streetinsider.com/Earnings/Enliven+Therapeutics%2C+Inc+%28ELVN%29+Tops+Q3+EPS+by+9c/27302355.html
Enliven Therapeutics, Inc (NASDAQ: ELVN) reported its Q3 EPS, coming in at ($0.36), which was $0.09 better than the analyst estimate of ($0.45). The stock price for ELVN was $49.43, reflecting a 10.36% increase today. The article highlights the positive surprise in earnings for the company.

Form 4 Enliven Therapeutics Inc: Lori Anne Kunkel (Director) For: 30 October By Investing.com

https://in.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-lori-anne-kunkel-director-for-30-october-93CH-5677153
This article reports on a Form 4 filing for Enliven Therapeutics Inc, indicating that Director Lori Anne Kunkel made a transaction on October 30. The filing is provided by Investing.com, a financial markets news source. The content is brief and focuses solely on this insider trading update.

A director exercised options at $1.12 and $18.30 at Enliven Therapeutics (ELVN).

https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-7391d0ff1a27.html
Lori Anne Kunkel, a director at Enliven Therapeutics (ELVN), exercised stock options on October 30, 2026. She acquired 3,741 common shares at $1.12 per share and 7,300 common shares at $18.30 per share. One option was fully vested, while the other vests monthly subject to her continued service as an outside director.

BlackRock reports sole voting power over 5.1M Enliven Therapeutics (ELVN) shares.

https://www.stocktitan.net/sec-filings/ELVN/schedule-13g-a-enliven-therapeutics-inc-amended-passive-investment-di-39369df0c2e8.html
BlackRock, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Enliven Therapeutics, Inc. (ELVN), reporting beneficial ownership of 5,206,581 common shares, which constitutes 7.1% of the class as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 5,097,086 shares and sole dispositive power over 5,206,581 shares. This update provides transparency on BlackRock's significant stake and control over a portion of Enliven Therapeutics' stock.

Enliven Therapeutics, Inc. Estimates – NASDAQ:ELVN

https://www.tradingview.com/symbols/NASDAQ-ELVN/financials-estimates/
This article provides an overview of Enliven Therapeutics, Inc. (NASDAQ:ELVN) financials on TradingView, covering reported financial data and analyst estimates. Users can explore income statements, balance sheets, cash flow, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also visualizes trends over time for annual and quarterly data.
Advertisement

Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock By Investing.com

https://za.investing.com/news/stock-market-news/enliven-therapeutics-cmo-collins-sells-192342-in-elvn-stock-93CH-4517939
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, sold 5,000 shares of ELVN stock for $192,342 on October 19, 2026, while also acquiring 5,000 shares through stock options exercise for $12,400. Both transactions were conducted under a Rule 10b5-1 trading plan. The company's stock has seen a 172% year-to-date return, and several analyst firms have reiterated "Buy" ratings and raised price targets following FDA alignment on a Phase 3 trial.

Form 4 Enliven Therapeutics Inc: Benjamin Hohl (CFO) For: 19 October

https://au.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-benjamin-hohl-cfo-for-19-october-93CH-4706020
This article reports on a Form 4 filing for Enliven Therapeutics Inc. related to its CFO, Benjamin Hohl, for October 19. It indicates insider trading activity for the company (ELVN).

After exercising options, Enliven Therapeutics (ELVN) CFO sells 6,018 shares under a trading plan.

https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-de64f441d454.html
Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, exercised 6,018 options and subsequently sold 6,018 common shares at a weighted average price of $38.4755 per share on October 19, 2026. These transactions were carried out under a Rule 10b5-1 trading plan established on March 18, 2026. Following these transactions, Hohl still holds 175,000 shares underlying options and 38,000 common shares directly.

Medical chief exercises $2.48 options and sells 5,000 shares at Enliven Therapeutics (ELVN).

https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-eaa020d72c0f.html
Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN), exercised options for 5,000 shares at $2.48 per share and simultaneously sold those shares at a weighted average price of $38.4684 per share on October 19, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted on October 19, 2025. Following the transaction, Collins still holds options for 101,268 shares.

Form 4 Enliven Therapeutics Inc: Helen Louise Collins (CHIEF MEDICAL OFFICER) For: 19 October

https://ng.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-helen-louise-collins-chief-medical-officer-for-19-october-93CH-2749820
This article reports on a Form 4 filing for Enliven Therapeutics Inc, detailing an insider transaction by Helen Louise Collins, the Chief Medical Officer, for October 19. Form 4 filings are regulatory documents disclosing changes in the ownership of securities by a company's directors, officers, and principal stockholders. The report includes the stock symbol ELVN and indicates a minor price change.
Advertisement

Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock By Investing.com

https://ng.investing.com/news/stock-market-news/enliven-therapeutics-cmo-collins-sells-192342-in-elvn-stock-93CH-2749817
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics (NASDAQ:ELVN), sold 5,000 shares of company stock for $192,342 on October 19, 2026, while also acquiring 5,000 shares through stock options for $12,400. These transactions were executed under a Rule 10b5-1 trading plan adopted a year prior. The company has also received multiple positive analyst ratings following its alignment with the FDA for its Phase 3 ENABLE-2 trial.

Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock By Investing.com

https://au.investing.com/news/stock-market-news/enliven-therapeutics-cmo-collins-sells-192342-in-elvn-stock-93CH-4705974
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics (NASDAQ:ELVN), sold 5,000 shares of the company's common stock for $192,342 on October 19, 2026, while simultaneously acquiring 5,000 shares through stock options for $12,400. The transactions were conducted under a Rule 10b5-1 trading plan. This comes as Enliven Therapeutics sees significant analyst optimism and progress in its clinical trials for relcobatinib.

Enliven Therapeutics Inc (ELVN-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/ELVN/
This article provides current stock price information and news updates for Enliven Therapeutics Inc. (ELVN-Q), a clinical-stage precision oncology company. The company focuses on developing small molecule kinase inhibitors, with lead candidates ELVN-001 and ELVN-002. Recent news highlights analyst ratings, director additions, and positive Phase 1 data for ELVN-001.

Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.

https://www.moomoo.com/news/post/1001577274/enliven-therapeutics-is-maintained-at-buy-by-hc-wainwright-co
HC Wainwright & Co. has reiterated its Buy rating for Enliven Therapeutics. This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.

HC Wainwright & Co. maintains Buy rating on Enliven Therapeutics, $73 price target

https://www.tradingview.com/news/tradingview:b6e55c2a54429:0-hc-wainwright-co-maintains-buy-rating-on-enliven-therapeutics-73-price-target/
HC Wainwright & Co. has reiterated its Buy rating on Enliven Therapeutics (ELVN) with a price target of $73.00, suggesting a significant upside from its current trading price. This positive outlook is supported by the anticipated ENABLE-2 trial, which is de-risked due to FDA alignment, and promising early results from the ENABLE trial showing superior efficacy of ELVN-001 against existing treatments for chronic myeloid leukemia.
Advertisement

Director Helen Collins plans to sell 15,000 Enliven Therapeutics (ELVN) shares.

https://www.stocktitan.net/sec-filings/ELVN/144-enliven-therapeutics-inc-sec-filing-4bc0958a14dc.html
Enliven Therapeutics director Helen Collins has filed notice to sell 15,000 common shares of ELVN, valued at $559,800, with an approximate sale date of October 19, 2026. This proposed sale is being conducted under a Rule 10b5-1 plan adopted on October 19, 2025. The filing also indicates previous sales of 5,000 shares each on August 17, 2026, and September 17, 2026.

H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73

https://www.moomoo.com/news/post/1001576781/hc-wainwright-maintains-enliven-therapeutics-elvnus-with-buy-rating-raises
H.C. Wainwright has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and increased its target price to $73. This indicates a positive outlook from the firm regarding the company's future performance and stock potential.

Form 4 Enliven Therapeutics Inc: Kristine M. Ball (Director) For: 14 October

https://ca.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-kristine-m-ball-director-for-14-october-93CH-4886314
This article reports on a Form 4 filing for Enliven Therapeutics Inc, indicating a transaction by Kristine M. Ball, a director of the company. The filing pertains to an event on October 14. The article provides the company's stock symbol, ELVN, and its current price performance.

[Form 3] Enliven Therapeutics, Inc. Initial Statement of Beneficial Ownership

https://www.stocktitan.net/sec-filings/ELVN/form-3-enliven-therapeutics-inc-initial-statement-of-beneficial-owner-c80e626fe3fd.html
This article reports on an Initial Statement of Beneficial Ownership (Form 3) filed by Kristine M. Ball for Enliven Therapeutics, Inc. (ELVN). The filing indicates her appointment as a Director on October 14, 2026, and states that she beneficially owns no securities. The document was accepted by SEC EDGAR on October 16, 2026, at 04:41 PM EDT.

A 23,394-option grant to director Ball at Enliven Therapeutics (ELVN) carries a $39.28 exercise price.

https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-07c903f5e3e6.html
Enliven Therapeutics (ELVN) director Kristine M. Ball was granted 23,394 stock options on October 14, 2026, with an exercise price of $39.28 per share. The options will vest monthly, with one thirty-sixth of the shares vesting on November 14, 2026, and each month thereafter, provided she continues as an outside director. These options are set to expire on October 14, 2036.
Advertisement

Enliven Therapeutics appoints Kristine Ball to board

https://www.investing.com/news/company-news/enliven-therapeutics-appoints-kristine-ball-to-board-93CH-4950033
Enliven Therapeutics (NASDAQ:ELVN) has appointed Kristine Ball to its Board of Directors, bringing over 20 years of biopharmaceutical executive experience. Her appointment comes as the company prepares to initiate a pivotal Phase 3 trial for relcobatinib (ELVN-001) in chronic myeloid leukemia patients. Ball's expertise in transitioning companies from clinical development to commercial operations will be valuable as Enliven advances its lead product candidate.

Enliven Therapeutics appoints Kristine Ball to Board and Audit Committee

https://www.tradingview.com/news/tradingview:e3b0629aa08b7:0-enliven-therapeutics-appoints-kristine-ball-to-board-and-audit-committee/
Enliven Therapeutics has appointed Kristine Ball as a Class II director and a member of its Audit Committee, effective October 14, 2026. This appointment increases the board's size from seven to eight directors. The information is based on an SEC filing from Enliven Therapeutics, Inc. [ELVN].

Enliven Therapeutics, Inc. (ELVN) Adds Kristine Ball to Board

https://www.tradingview.com/news/tradingview:af89fe7e68ae9:0-enliven-therapeutics-inc-elvn-adds-kristine-ball-to-board/
Enliven Therapeutics (ELVN) has appointed Kristine Ball to its Board of Directors as it prepares for the pivotal Phase 3 ENABLE-2 trial of relcobatinib for CML, expected to start before year-end 2026. This strategic board addition, featuring Ball's CFO/CEO experience, aims to support the company's transition into late-stage development and pre-commercialization efforts. The FDA's alignment on the trial's design helps reduce execution risks for the upcoming Phase 3 study.

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

https://www.prnewswire.com/news-releases/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year-302909108.html
Enliven Therapeutics has appointed Kristine Ball to its Board of Directors, bringing over 20 years of executive experience in biopharmaceutical companies. This appointment comes as Enliven prepares to initiate a pivotal Phase 3 trial for its drug relcobatinib (ELVN-001) in patients with chronic myeloid leukemia (CML) before the end of 2026, following recent FDA alignment on the trial design. Ball's expertise in corporate strategy, finance, and commercial readiness is expected to be crucial as the company transitions from clinical development to potential commercialization.

Enliven Therapeutics adds Kristine Ball to its board of directors

https://www.streetinsider.com/Board+Changes/Enliven+Therapeutics+adds+Kristine+Ball+to+its+board+of+directors/27187485.html
Enliven Therapeutics has appointed Kristine Ball to its board of directors, effective immediately. Ball brings over 20 years of executive experience in the biopharmaceutical industry and will provide valuable perspective as Enliven prepares to initiate its pivotal Phase 3 trial of relcobatinib (ELVN-001) for chronic myeloid leukemia before the end of 2026. The company has received FDA alignment on the trial's design.
Advertisement

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

https://www.morningstar.com/news/pr-newswire/20261014la72291/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year
Enliven Therapeutics (Nasdaq: ELVN) has appointed Kristine Ball to its Board of Directors. Ms. Ball brings over 20 years of biopharmaceutical executive experience in corporate strategy, finance, and commercial readiness. Her appointment comes as Enliven prepares to initiate its pivotal Phase 3 trial of relcobatinib for chronic myeloid leukemia patients before the end of 2026 and plans for future commercialization.

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

https://www.trinityjournal.com/online_features/press_releases/article_e054c2cd-f29e-53a2-839c-d137040b7631.html
Enliven Therapeutics has appointed Kristine Ball to its Board of Directors, leveraging her extensive experience in corporate strategy, finance, and commercial readiness. This appointment comes as Enliven prepares to initiate a pivotal Phase 3 trial for relcobatinib, its chronic myeloid leukemia (CML) treatment, before the end of 2026. Ms. Ball's expertise will be crucial in guiding the company's transition from clinical development to potential commercialization, aiming to provide a differentiated treatment option for CML patients and enhance shareholder value.

Form 4 Enliven Therapeutics Inc For: 12 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-for-12-october-93CH-2730821
This article reports on a Form 4 filing for Enliven Therapeutics Inc. for October 12. Form 4 filings are legally required documents filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their beneficial ownership of the company's stock. The article itself does not provide details of the filing but indicates its publication by Investing.com.

Enliven Therapeutics director Scott Garland sells $606k in stock By Investing.com

https://ng.investing.com/news/stock-market-news/enliven-therapeutics-director-scott-garland-sells-606k-in-stock-93CH-2730817
Scott Garland, a director at Enliven Therapeutics (NASDAQ:ELVN), sold 13,000 shares of the company's common stock for a total of $606,719 after exercising stock options. The shares were sold at a weighted average price of $46.6707, with the stock currently trading at $40.98. Despite the recent dip, the stock has shown a strong 97% return over the past year, though InvestingPro analysis suggests it may be overvalued.

Form 4 Enliven Therapeutics Inc For: 12 October By Investing.com

https://in.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-for-12-october-93CH-5627609
This article announces the filing of a Form 4 for Enliven Therapeutics Inc. on October 12. It is a brief, standard news item from Investing.com, likely indicating an insider transaction or change in ownership that requires disclosure. The article primarily serves as a notification without providing further details on the Form 4's contents.
Advertisement

Enliven Therapeutics director Scott Garland sells $606k in stock By Investing.com

https://ca.investing.com/news/stock-market-news/enliven-therapeutics-director-scott-garland-sells-606k-in-stock-93CH-4875169
Scott Garland, a director at Enliven Therapeutics (NASDAQ:ELVN), sold 13,000 shares of company stock for over $606,000 on October 1, 2026, after exercising stock options. Despite the stock trading down nearly 10% recently, it has seen a 97% return over the past year. Analysts from Guggenheim, Morgan Stanley, JPMorgan, William Blair, and Barclays have initiated or reiterated positive ratings on Enliven Therapeutics, following FDA agreement on its Phase 3 study for relcobatinib.

Form 4 Enliven Therapeutics Inc For: 12 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-for-12-october-93CH-4875173
This article announces the filing of a Form 4 by Enliven Therapeutics Inc. on October 12, as reported by Investing.com. It is a very brief notification without additional details, serving mainly as an announcement of the regulatory filing for the company. The text mostly consists of navigation, advertisements, and market data rather than specific information about the Form 4.

The Technical Signals Behind (ELVN) That Institutions Follow

https://news.stocktradersdaily.com/news_release/52/The_Technical_Signals_Behind_ELVN_That_Institutions_Follow_101126020002_1791741602.html
This article analyzes the technical signals for Enliven Therapeutics Inc. (NASDAQ: ELVN), noting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The analysis indicates elevated downside risk due to a lack of additional long-term support signals.

The FDA aligned with Enliven on a leukemia trial design for about 450 adults, with a start planned before year-end.

https://www.stocktitan.net/news/ELVN/enliven-therapeutics-announces-fda-alignment-on-enable-2-phase-3-auxiyx3niike.html
Enliven Therapeutics has reached FDA alignment on the design of ENABLE-2, a Phase 3 trial for relcobatinib (ELVN-001) in chronic myeloid leukemia. This trial will enroll approximately 450 adults previously treated with tyrosine kinase inhibitors, randomizing them to receive relcobatinib or an investigator-selected second-generation inhibitor. The primary endpoint is major molecular response at Week 24, and Enliven plans to initiate the trial before the end of 2026.

Enliven Therapeutics Announces FDA Alignment On ENABLE-2 Pivotal Phase 3 Trial Design For Relcobatinib In Previously Treated Chronic Myeloid Leukemia

https://www.marketscreener.com/news/enliven-therapeutics-announces-fda-alignment-on-enable-2-pivotal-phase-3-trial-design-for-relcobatin-ce785dd9d18df327
Enliven Therapeutics has received FDA alignment on the design for its ENABLE-2 pivotal Phase 3 trial of relcobatinib (ELVN-001) for patients with previously treated chronic myeloid leukemia (CML). Relcobatinib, now officially named, is a potent and selective kinase inhibitor targeting the BCR::ABL1 gene fusion. The randomized trial will enroll approximately 450 adults, comparing relcobatinib to investigator-selected second-generation TKIs, with major molecular response at Week 24 as the primary endpoint.
Advertisement

Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial

https://finance.yahoo.com/healthcare/articles/enliven-therapeutics-reaches-realignment-fda-090147201.html
Enliven Therapeutics (ELVN) has reached an agreement with the FDA on the final design of its Phase 3 trial for relcobatinib. The company is now on track to initiate the trial for patients with an unspecified condition. The full details are available to subscribers of premium news services.

Enliven Therapeutics (ELVN) Gets FDA Alignment on ENABLE-2 Phase 3 Design

https://www.tradingview.com/news/tradingview:8e57c414d3879:0-enliven-therapeutics-elvn-gets-fda-alignment-on-enable-2-phase-3-design/
Enliven Therapeutics (ELVN) announced FDA alignment on the ENABLE-2 Phase 3 trial design for relcobatinib (ELVN-001) for previously treated chronic myeloid leukemia. This regulatory milestone signals Phase 3 readiness, de-risking trial planning and timelines. The asset, relcobatinib, is a key pipeline driver for the company.

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-fda-alignment-on-enable-2-phase-3-trial-design-for-relcobatinib-elvn-001-in-previously-treated-chronic-myeloid-leukemia-302900300.html
Enliven Therapeutics has announced FDA alignment on the design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib (ELVN-001), a treatment for previously treated chronic myeloid leukemia (CML). The trial will compare relcobatinib to second-generation TKIs in approximately 450 adult CML patients, with major molecular response (MMR) at Week 24 as the primary endpoint. Enliven plans to initiate the ENABLE-2 trial before the end of 2026.

After exercising options at $15.47, Enliven Therapeutics (ELVN) director sells 13,000 shares.

https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-335ed927842e.html
Enliven Therapeutics (ELVN) director J. Scott Garland exercised options for 13,000 shares at $15.47 per share and subsequently sold all 13,000 shares at a weighted average price of $46.6707 per share. This transaction resulted in an approximate pre-tax spread of $406,000. Following the exercise, Garland's reported option position was 46,372 shares, with no common stock held directly.

Morgan Stanley Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70

https://www.moomoo.com/news/post/1000608424/morgan-stanley-maintains-enliven-therapeutics-elvnus-with-buy-rating-maintains
Morgan Stanley has reiterated its "Buy" rating for Enliven Therapeutics (ELVN.US) and maintained its price target of $70. This indicates a continued positive outlook from the financial firm on the company's stock performance.
Advertisement

Enliven Therapeutics Director Sold Shares Worth Over $606K

https://www.tradingview.com/news/tradingview:c1035fd61f835:0-enliven-therapeutics-director-sold-shares-worth-over-606k/
A director at Enliven Therapeutics, Garland J. Scott, reported selling 13,000 shares of common stock for a total of $606,719. The shares were sold on 2026-10-01 at an average price of $46.6707 per share, and following this transaction, the reporting person no longer directly owns common stock in the company.

Why Is Enliven Therapeutics (NASDAQ:ELVN) Moving Back Into Focus?

https://kalkinemedia.com/us/stocks/penny/why-is-enliven-therapeutics-nasdaqelvn-moving-back-into-focus
Enliven Therapeutics (NASDAQ:ELVN) is gaining attention as selective risk appetite shifts towards smaller companies with clear milestones, financial transparency, and reliable customers. The key question for the company is whether its precision oncology medicines can ensure consistent execution and growth. While market trends provide context, the company's specific progress and disclosures are more critical for investors to evaluate its long-term potential.

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

https://www.webull.com/news/15678621673800704
This article highlights new analyst coverage for several companies, with Morgan Stanley initiating Enliven Therapeutics (NASDAQ: ELVN) with an Overweight rating and a $70 price target. Other companies receiving new coverage include Vylor, Inc. (NYSE: VYLR), LB Pharmaceuticals Inc (NASDAQ: LBRX), Sailpoint Inc (NASDAQ: SAIL), and Avalyn Pharma Inc (NASDAQ: AVLN), with ratings ranging from Outperform to Sector Weight. These initiations provide new outlooks and price targets for investors to consider.

Enliven Therapeutics Price Target Announced at $70.00/Share by Morgan Stanley

https://www.moomoo.com/news/post/1000548869/enliven-therapeutics-price-target-announced-at-70-00-share-by
Morgan Stanley has set a price target of $70.00 per share for Enliven Therapeutics. This target provides investors with a specific valuation outlook from a major financial institution.

Enliven Therapeutics Initiated at Overweight by Morgan Stanley

https://www.moomoo.com/news/post/1000548867/enliven-therapeutics-initiated-at-overweight-by-morgan-stanley
Morgan Stanley has initiated coverage on Enliven Therapeutics with an "Overweight" rating. This indicates a positive outlook from the investment bank regarding the company's stock performance.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement